GLP-1RA: where do they fit in CV risk management?

10' education - Oct. 21, 2019 - Prof. John Deanfield, MD - London, UK

Video navigation menu

Diabetes treatment for CVD reduction in patients with CVD 0:45
T2DM without clinical CVD 3:50
Clinical CVD without T2DM 5:29
Why uptake of the new agents is low in cardiology and how this can be overcome 6:58
Exciting new era for CVD managment (in T2DM) 9:24

Educational information

This lecture held by prof.Deanfield was part of an accredited symposium "Transforming diabetes management in cardiology: Impact of novel therapies" held during ESC Congress 2019 in Paris, France.

Faculty

Prof. Deanfield - Professor of Cardiology at University College London (UCL) and Consultant Cardiologist at the Barts Heart Centre (BHC) London UK. He is the Director of the National Centre for Cardiovascular disease Prevention and Outcomes (NCCPO) at UCL, and Chairman of National Institute for Cardiovascular (CV) Outcomes Research (NICOR).

Disclosures

This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk A/S.

View the slides of this presentation

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.